All In Biotech

NDA 205053 · Merck Sharp Dohme

Noxafil

Posaconazole · Oral · Azole Antifungal

OrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Jan 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Nov 25, 2013

Approved uses

4

Original approval plus efficacy supplements

Registered trials

90

20 Phase 3, 19 recruiting

FAERS reports

16,564

14,256 serious, 3,927 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 18, 2026.

Posaconazole is an azole antifungal indicated as follows: Posaconazole delayed-release tablets are indicated for the treatment of invasive aspergillosis in adults and pediatric patients 2 years of age and older who weigh greater than 40 kg. ( 1.1 ) Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: ( 1.2 ) Posaconazole delayed-release tablets : adults and pediatric patients 2 years of age and older who weigh greater than 40 kg Posaconazole oral suspension: adults and pediatric patients 13 years of age and older Posaconazole oral suspension is indicated for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory (rOPC) to itraconazole and/or fluconazole in adults and pediatric patients 13 years of age and older. ( 1.3 ) 1.1 Treatment of Invasive Aspergillosis Posaconazole delayed-release tablets are indicated for the treatment of invasive aspergillosis in adults and pediatric patients 2 years of age and older who weigh greater than 40 kg. 1.2 Prophylaxis of Invasive Aspergillus and Candida Infections Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy [see Clinical Studies (14.1) ] as follows:...

Mechanism: Posaconazole is an azole antifungal agent [see Clinical Pharmacology (12.4) ] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NOXAFIL · POSACONAZOLE 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, DELAYED RELEASE, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Posaconazole" as an intervention, any sponsor and status, largest first.

All 90 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,706
  • drug ineffective1,513
  • febrile neutropenia1,099
  • product use in unapproved indication1,074
  • drug interaction1,042
  • death993
  • pyrexia921
  • neutropenia770
  • pneumonia698
  • thrombocytopenia551
  • diarrhoea550
  • nausea536

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
200522
200633
2007113
2008116
2009154
2010115
2011182
2012249
2013249
2014407
2015503
2016631
2017930
20181,101
20191,229
20201,363
20211,534
20221,529
20231,576
20241,684
20251,671
20261,170

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Noxafil* (Posaconazole)

2024 spending

$632K

Beneficiaries

84

146 claims

Per beneficiary

$7,530

$58.66 per unit

View as table
YearSpending
2020$15,485,827
2021$7,985,674
2022$5,375,749
2023$2,509,595
2024$632,487

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 210 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.